| Symbol | CNTA |
|---|---|
| Name | CENTESSA PHARMACEUTICALS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1 ASHLEY ROAD,3RD FLOOR, CHESHIRE, WA14 2DT, United Kingdom |
| Telephone | +44 2039206789 |
| Fax | — |
| — | |
| Website | https://www.centessa.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001847903 |
| Description | Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others. Additional info from NASDAQ: |
New Form ARS - Centessa Pharmaceuticals plc <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001847903-26-000041 <b>Size:</b> 27 MB
Read moreNew Form DEF 14A - Centessa Pharmaceuticals plc <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001847903-26-000040 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - Centessa Pharmaceuticals plc <b>Filed:</b> 2026-04-13 <b>AccNo:</b> 0001193125-26-153121 <b>Size:</b> 32 KB
Read moreSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)
Read moreCentessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
Read more(10% Negative) CENTESSA PHARMACEUTICALS PLC (CNTA) Announces Business Combination
Read moreNew Form DEFA14A - Centessa Pharmaceuticals plc <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001193125-26-134758 <b>Size:</b> 46 KB
Read moreNew Form DEFA14A - Centessa Pharmaceuticals plc <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001193125-26-134750 <b>Size:</b> 23 KB
Read moreNew Form DEFA14A - Centessa Pharmaceuticals plc <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001193125-26-134740 <b>Size:</b> 25 KB
Read moreNew Form DEFA14A - Centessa Pharmaceuticals plc <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001193125-26-134727 <b>Size:</b> 28 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07413666 | A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years | Phase1 | Healthy Adult Male and Female Volunteers | Recruiting | 2026-02-25 | 2027-06-30 | ClinicalTrials.gov |
| NCT07096674 | A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiop… | Phase2 | Narcolepsy Type 1 | Recruiting | 2025-08-12 | 2026-04-30 | ClinicalTrials.gov |
| NCT07082829 | A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years … | Phase1 | Excessive Daytime Sleepiness | Recruiting | 2025-06-30 | 2026-06-15 | ClinicalTrials.gov |
| NCT06752668 | A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | Phase2 | Narcolepsy Type 1 | Recruiting | 2024-12-23 | 2026-12-01 | ClinicalTrials.gov |
| NCT06568302 | The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who C… | Phase3 | Hemophilia a | Terminated | 2024-07-11 | 2025-01-29 | ClinicalTrials.gov |
| NCT05789537 | A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors | Phase2 | Hemophilia B with Inhibitor | Terminated | 2023-07-28 | 2025-02-24 | ClinicalTrials.gov |
| NCT05789524 | The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or… | Phase2 | Hemophilia a | Terminated | 2023-07-06 | 2025-02-28 | ClinicalTrials.gov |
| NCT05821777 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in P… | Phase1 | Advanced Solid Tumor | Terminated | 2023-03-28 | 2025-09-09 | ClinicalTrials.gov |
| NCT05605678 | Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5) | — | Hemophilia a | Terminated | 2022-12-09 | 2024-11-29 | ClinicalTrials.gov |
| NCT05323110 | Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in He… | Phase1 | Chronic Inflammatory Disease | Terminated | 2022-04-14 | 2023-08-22 | ClinicalTrials.gov |
| NCT05208866 | Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who C… | Phase3 | Polycystic Kidney Disease, Adult | Terminated | 2022-02-10 | 2022-07-29 | ClinicalTrials.gov |
| NCT04064346 | Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycy… | Phase3 | Autosomal Dominant Polycystic Kidney | Terminated | 2021-10-28 | 2022-08-03 | ClinicalTrials.gov |
| NCT04152837 | Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosoma… | Phase3 | Polycystic Kidney Disease, Adult | Terminated | 2020-09-02 | 2022-07-29 | ClinicalTrials.gov |
| NCT04443192 | A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers … | Phase1 | Alpha1 Anti-Trypsin Deficiency | Terminated | 2020-08-03 | 2022-09-12 | ClinicalTrials.gov |
| NCT04073498 | The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe B… | Phase1 | Hemophilia a | Completed | 2019-08-14 | 2024-09-26 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Alpha1 Anti-Trypsin Deficiency | TERMINATED | NCT04443192 |
| ZF874 | Other | Phase PHASE1 | Alpha1 Anti-Trypsin Deficiency | TERMINATED | NCT04443192 |
| Placebo | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT04064346 |
| Lixivaptan | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT04064346 |
| Lixivaptan | Other | Phase PHASE3 | Polycystic Kidney Disease, Adult | TERMINATED | NCT04152837 |
| Lixivaptan | Other | Phase PHASE3 | Polycystic Kidney Disease, Adult | TERMINATED | NCT05208866 |
| Placebo | Other | Phase PHASE1 | Chronic Inflammatory Disease | TERMINATED | NCT05323110 |
| CBS001 | Other | Phase PHASE1 | Chronic Inflammatory Disease | TERMINATED | NCT05323110 |
| Placebo | Other | Phase PHASE1 | Hemophilia a | COMPLETED | NCT04073498 |
| SerpinPC | Other | Phase PHASE1 | Hemophilia a | COMPLETED | NCT04073498 |
| No Intervention | Other | Preclinical | Hemophilia a | TERMINATED | NCT05605678 |
| SerpinPC | Other | Phase PHASE3 | Hemophilia a | TERMINATED | NCT06568302 |
| SerpinPC | Other | Phase PHASE2 | Hemophilia B with Inhibitor | TERMINATED | NCT05789537 |
| SerpinPC | Other | Phase PHASE2 | Hemophilia a | TERMINATED | NCT05789524 |
| LB101 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05821777 |
| LB101 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05821777 |
| Placebo Tablets | Other | Phase PHASE1 | Excessive Daytime Sleepiness | RECRUITING | NCT07082829 |
| ORX142 Tablets | Other | Phase PHASE1 | Excessive Daytime Sleepiness | RECRUITING | NCT07082829 |
| Placebo Tablets | Other | Phase PHASE1 | Excessive Daytime Sleepiness | RECRUITING | NCT07082829 |
| ORX142 Tablets | Other | Phase PHASE1 | Excessive Daytime Sleepiness | RECRUITING | NCT07082829 |
| Placebo Tablets | Other | Phase PHASE1 | Healthy Adult Male and Female Volunteers | RECRUITING | NCT07413666 |
| ORX489 Tablets | Other | Phase PHASE1 | Healthy Adult Male and Female Volunteers | RECRUITING | NCT07413666 |
| Placebo Tablets | Other | Phase PHASE1 | Healthy Adult Male and Female Volunteers | RECRUITING | NCT07413666 |
| ORX489 Tablets | Other | Phase PHASE1 | Healthy Adult Male and Female Volunteers | RECRUITING | NCT07413666 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07096674 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07096674 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07096674 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07096674 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07096674 |
| ORX750 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07096674 |
| LB101 | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05821777 |
| ORX142 Tablets | DRUG | Phase PHASE1 | Excessive Daytime Sleepiness | RECRUITING | NCT07082829 |
| Placebo Tablets | OTHER | Phase PHASE1 | Excessive Daytime Sleepiness | RECRUITING | NCT07082829 |
| ORX489 Tablets | DRUG | Phase PHASE1 | Healthy Adult Male and Female Volunteers | RECRUITING | NCT07413666 |
| ORX750 | DRUG | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| No Intervention | OTHER | Preclinical | Hemophilia a | TERMINATED | NCT05605678 |
| CBS001 | DRUG | Phase PHASE1 | Chronic Inflammatory Disease | TERMINATED | NCT05323110 |
| ZF874 | DRUG | Phase PHASE1 | Alpha1 Anti-Trypsin Deficiency | TERMINATED | NCT04443192 |
| SerpinPC | DRUG | Phase PHASE3 | Hemophilia a | TERMINATED | NCT06568302 |
| Placebo | DRUG | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT06752668 |
| Lixivaptan | DRUG | Phase PHASE3 | Polycystic Kidney Disease, Adult | TERMINATED | NCT05208866 |